Cargando…
Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Nature Singapore
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436721/ https://www.ncbi.nlm.nih.gov/pubmed/36050376 http://dx.doi.org/10.1038/s41422-022-00713-y |
| _version_ | 1784781434182959104 |
|---|---|
| author | Hoffmann, Markus Jin, Yeonhwa Pöhlmann, Stefan |
| author_facet | Hoffmann, Markus Jin, Yeonhwa Pöhlmann, Stefan |
| author_sort | Hoffmann, Markus |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9436721 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Nature Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94367212022-09-02 Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment Hoffmann, Markus Jin, Yeonhwa Pöhlmann, Stefan Cell Res Correction Springer Nature Singapore 2022-09-01 /pmc/articles/PMC9436721/ /pubmed/36050376 http://dx.doi.org/10.1038/s41422-022-00713-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Hoffmann, Markus Jin, Yeonhwa Pöhlmann, Stefan Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment |
| title | Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment |
| title_full | Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment |
| title_fullStr | Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment |
| title_full_unstemmed | Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment |
| title_short | Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment |
| title_sort | publisher correction: dalbavancin: novel candidate for covid-19 treatment |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436721/ https://www.ncbi.nlm.nih.gov/pubmed/36050376 http://dx.doi.org/10.1038/s41422-022-00713-y |
| work_keys_str_mv | AT hoffmannmarkus publishercorrectiondalbavancinnovelcandidateforcovid19treatment AT jinyeonhwa publishercorrectiondalbavancinnovelcandidateforcovid19treatment AT pohlmannstefan publishercorrectiondalbavancinnovelcandidateforcovid19treatment |